(112 days)
Not Found
Not Found
No
The summary describes a qualitative in vitro diagnostic test for drug screening, which typically relies on chemical reactions and visual interpretation, not AI/ML. There are no mentions of AI, ML, image processing, or data sets for training/testing.
No
This device is an in vitro diagnostic test used for the qualitative detection of Phencyclidine in human urine, which is a diagnostic purpose, not a therapeutic one. It does not treat or cure a disease or condition.
Yes
This device is an in vitro screen test for the qualitative detection of Phencyclidine, which is used to identify the presence of a specific substance in human urine, aiding in the diagnosis of drug use.
No
The device is an In Vitro Diagnostic (IVD) test kit, which is a physical product used to analyze a biological sample (urine). It is not described as software.
Yes, based on the provided information, the Ameditech ImmuTest™ Drug Screen PCP is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The "Intended Use / Indications for Use" section explicitly states it is an "In Vitro screen test for the qualitative detection of Phencyclidine in human urine".
- In Vitro: "In Vitro" means "in glass" or "outside of the body". This test is performed on a sample (urine) taken from the body, not directly on the body itself.
- Diagnostic: While it's a "screen test" and provides a "qualitative result", it is used to detect the presence of a substance (Phencyclidine) that can be indicative of drug use, which falls under the broad category of diagnostic testing.
Therefore, the description clearly aligns with the definition of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The Ameditech ImmuTest™ Drug Screen PCP is an In Vitro screen test for the qualitative detection of Phencyclidine in human urine at cut-off concentration of 25 ng/ml. This test kit is used to obtain a visual, qualitative result and is intended for professional use.
Product codes
LCM
Device Description
Not Found
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
professional use.
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Not Found
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Not Found
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
N/A
0
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular border with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the top half of the circle. Inside the circle is a stylized symbol resembling three wavy lines or a bird in flight.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
John Wu, Ph.D. Director of Quality Assurance Ameditech, Inc. 10340 Camino Santa Fe, Suite F San Diego, CA 92121
NOV 3 0 2001
K012582 Re: Trade/Device Name: Ameditech ImmuTest™ Drug Screen PCP Regulatory Number: Unclassified Product Code: LCM Dated: October 24, 2001 Received: October 31, 2001
Dear Dr. Wu:
We have reviewed your Section 510(k) premarket notification of intent to market the device wo have a rowe and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate for ass stated in the May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The I ou may, atere, and servisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must or any I vithe Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set Orth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
1
Page 2 -
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed notification. The I Dri intellig of succion for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFFR Part 801 and 1 II you desire specific acrice for your actic devices), please contact the Office of Compliance at additionally 809.10 for m viro diagliestions on the promotion and advertising of your device, (201) 594-4566. Additionally, For quice at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small information on your responsionales and cranse at its toll-free number (800) 638-2041 or Manufacturers International and Sollass "http://www.fda.gov/cdrh/dsma/dsmamain.html".
Sincerely yours,
Steven Sutman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory-Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Page of
510(k) Number (if known): Kola582
Ameditech ImmuTest™ Drug Screen PCP Device Name:
Indications For Use:
The Ameditech ImmuTest™ Drug Screen PCP is an In Vitro screen test for the qualitative detection of Phencyclidine in human urine at cut-off concentration of 25 ng/ml.
This test kit is used to obtain a visual, qualitative result and is intended for professional use.
(Division Sign-Off)
Division of Clinical Laboratory Devices
510(k) Number K012582
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use
(Per 21 CFR 801.109)
OR
Over-The-Counter Use (Optional Format 1-2-96)